Production (Stage)
D
Connect Biopharma Holdings Limited CNTB
$0.95 $0.1011.77% NASDAQ
Recommendation
Prev Close
$0.95
Volume
457,759
Avg Vol (90D)
97,755
Market Cap
$52.78M
Dividend & Yield
--
52-Week Range
$0.51 - $1.79
P/E (TTM)
--
EPS (TTM)
-$0.609
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
6/13/2025 - Globe Newswire
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
6/3/2025 - Globe Newswire
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Up 56.5% in May
6/1/2025 - Ticker Report
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
5/28/2025 - Globe Newswire
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
5/20/2025 - Globe Newswire
Connect Biopharma Holdings First Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.069 profit in 1Q 2024)
5/17/2025 - Simply Wall St
Connect Biopharma Advances Asthma and COPD Treatments
5/17/2025 - TipRanks Financial Blog
Connect Biopharma Posts Wider Loss In Q1
5/15/2025 - RTT News - Earnings
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
5/15/2025 - Globe Newswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
5/14/2025 - Globe Newswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
5/13/2025 - Globe Newswire
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Sees Significant Increase in Short Interest
4/28/2025 - Ticker Report
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
4/24/2025 - Globe Newswire
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Update
4/17/2025 - Ticker Report
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
4/1/2025 - Globe Newswire
Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Connect Biopharma Holdings (CNTB)
4/1/2025 - TipRanks Financial Blog
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
3/31/2025 - Globe Newswire
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
3/31/2025 - Globe Newswire
Connect Biopharma Receives Nasdaq Deficiency Notice
3/28/2025 - TipRanks Financial Blog
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
3/28/2025 - Globe Newswire
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Up 56.7% in February
3/16/2025 - Ticker Report
Connect Biopharma to Present at Two Upcoming Investor Conferences
3/3/2025 - Globe Newswire
Connect Biopharma Holdings And Two Other Promising Penny Stocks To Watch
2/28/2025 - Simply Wall St
Connect Biopharma (NASDAQ:CNTB) Shares Down 0.8% - Should You Sell?
1/21/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$92.69M
Total Debt (Q)
$940.00K
Total Liabilities (Q)
$9.79M
Book Value Per Share (Q)
$1.50
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, May 15, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Sep 1 and 5 (est)
Price History
Loading...
Beta
-0.12
7-Day Total Return
21.78%
30-Day Total Return
15.14%
60-Day Total Return
15.11%
90-Day Total Return
-9.52%
Year to Date Total Return
-21.49%
1-Year Total Return
-40.63%
2-Year Total Return
-5.95%
3-Year Total Return
30.14%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $0.51
52-week High
Jun 14, 2024 - $1.79
Valuation
Market Cap
$52.78M - Micro Cap
Enterprise Value
-$30.27M
Price/Sales (TTM)
27.46
Price/Book (Q)
0.63
Dividends and Shares
Shares Outstanding
55.35M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.connectbiopharm.com
Phone Number
858 727 1040
Address
3580 CARMEL MOUNTAIN ROAD
San Diego, CA 92130
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is... more
NASDAQ 06/13/2025 3:59PM Eastern Quotes delayed